Biodexa announces filing of cta in europe for phase 3 serenta trial in familial adenomatous polyposis (fap)

July 14, 2025 biodexa announces filing of cta in europe for phase 3 serenta trial in familial adenomatous polyposis (fap) biodexa pharmaceuticals plc (“biodexa” or “the company”), (nasdaq: bdrx), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announced the filing of a clinical trial application (cta) with the european medicines agency (ema) for its serenta trial in patients with familial adenomatous polyposis (fap), a mostly inherited disease that, if left untreated, almost always leads to colorectal cancer. the only current treatment option is sequential resection of much of the gastrointestinal tract.
BDRX Ratings Summary
BDRX Quant Ranking